Jazz Pharmaceuticals plc — Director's Dealing 2025

Dec 11, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2025-12-09

Reporting Person: Henderson Mary Elizabeth (SVP, Technical Operations)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-12-09	Ordinary Shares	S	2238	$169.511	Disposed	19508	Direct

Footnotes

F1: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $169.00 to $169.82. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.